|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Rheumatoid Arthritis - Biologics Battle Up the Treatment Algorithm
Datamonitor, Sep 2006, Pages: 181
Rheumatoid arthritis is a debilitating and life-long disease that is estimated to affect approximately 5 million people in the seven major markets. The launch of anti-TNF products over six years ago and more recent novel target biologic therapies have added significantly to the treatment options, but have resulted in a crowded market for moderate to severe patients.
Scope of this title:
- Disease overview including epidemiology, physician estimated diagnosis rates and severity split, including mild to severe and early active disease
- Breakdown of treatment trends in the following markets: US, Japan, France, Germany, Italy, Spain and the UK
- PCPs and rheumatologists surveyed to capture the treatment of the ranging severities with traditional NSAIDs, COX-2s, traditional and biologic DMARDs
- Comparative brand assessment on the key attributes of Enbrel, Remicade, Humira, Orencia, Rituxan/MabThera, Kineret and methotrexate
Report Highlights
- Inclusion of relevant early active RA patients in clinical studies will assist timely approval in this indication, increasing the patient base for any RA product. Definition of ‘early’ RA requires a balance between the physician ideal of less than 12 months, giving the best patient response, and capturing a substantial proportion of the market.
- Physicians estimate nine months from disease onset to diagnosis. 25% of RA patients are estimated to be severe, and take an average of four months before the first DMARD is prescribed, being methotrexate in 60% of physicians. It can be 18-23 months before a severe patient is likely to use a biologic.
- Anti-TNF therapy is expected to continue to dominate the first-line biologic use. Humira is perceived to be the most effective in terms of disease modification, indicating a very positive future status for this brand, but Remicade and Kineret could lose the brand battle if perception on certain attributes doesnt improve.
Reasons to order your copy:
- Use estimated treatment class patient numbers to forecast product use across the seven major markets
- Exploit physician perceptions of key brands on clinical and market attributes, to differentiate products in the crowded rheumatoid arthritis market
- Understand differential treatment in niche populations such as severe and early active rheumatoid arthritis
Products Mentioned:
Enbrel (etanercept)
Remicade (infliximab)
Humira (adalimumab)
Kineret (anakinra)
Orencia (abatacept)
Rituxan/MabThera (rituximab)
Customers who bought this item also bought
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Competition For The Anti-TNF Failure Patient Population Increases
Physician Perception of Biologics in Autoimmune Disease - Targeted Detailing is the Key to Success
Treatment Algorithms: Rheumatoid Arthritis 2nd Edition - Dmards Move to Front of Pack
Stakeholder Insight: Inflammatory Bowel Disease - Debate over early aggressive treatment continues
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Stakeholder Insight: Rheumatoid Arthritis - DMARDs Gain Ground as Biologics Competition Intensifies
Prescribing for Elderly Patients
Psoriasis - Biologics are Yet to Make Topical Treatments Obsolete
Autoimmune Treatment (2009 - 2014)
Disease Modification In Rheumatoid Arthritis - Pipeline Uptake Inhibited By Anti-Tnfs
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
|
|
|
|
